本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Cellectis S.A.

4.42
+0.38009.41%
盤後4.31-0.1100-2.49%19:13 EDT
成交量:16.93萬
成交額:75.12萬
市值:4.42億
市盈率:-7.41
高:4.55
開:4.36
低:4.29
收:4.04
52周最高:4.59
52周最低:1.10
股本:1.00億
流通股本:6,690.99萬
量比:0.74
換手率:0.25%
股息:- -
股息率:- -
每股收益(TTM):-0.5967
每股收益(LYR):-0.4059
淨資產收益率:-48.02%
總資產收益率:-7.43%
市淨率:4.55
市盈率(LYR):-10.89

資料載入中...

公司資料

公司名字:
Cellectis S.A.
交易所:
NASDAQ
成立時間:
1999
員工人數:
219
公司地址:
8, rue de la Croix Jarry,Paris,Ile-de-France,France
郵編:
75013
傳真:
- -
簡介:
Cellectis S.A.於2000年1月4日成立。該公司是一家處於臨床階段的生物技術公司,利用他們的核心專有技術開發基於基因編輯的產品,擁有一系列同種異體嵌合抗原受體T細胞,即免疫腫瘤學領域的候選產品和基因編輯造血干細胞和祖細胞,即HSPC,其他治療適應症的候選產品。

董事

名稱
職位
Andre Choulika
Director, Chief Executive Officer and Co-Founder
Jean Pierre Garnier
Chairman of the Board and Director
David Sourdive
Director, Executive Vice President, Strategic Initiatives and Co-Founder
Alain Godard
Director
Annick Schwebig
Director
Herve Hoppenot
Director
Laurent Arthaud
Director
Pierre Bastid
Director
Rainer Boehm
Director

股東

名稱
職位
Andre Choulika
Director, Chief Executive Officer and Co-Founder
Eric Dutang
Chief Financial Officer
Leopold Bertea
Senior Vice President of Europe Technical Operations
Steven Doares
Senior Vice President of US Manufacturing
Arthur Stril
Chief Business Officer
Carrie Brownstein
Chief Medical Officer
David Sourdive
Director, Executive Vice President, Strategic Initiatives and Co-Founder
Jon Voss
Executive Vice President Global Quality
Kyung Nam Wortman
Chief Human Resources Officer
Marie Bleuenn Terrier
General Counsel
Philippe Duchateau
Chief Scientific Officer
Stephan Reynier
Chief Regulatory,Pharmaceutical Compliance Officer